Advancing immunology, transforming tomorrow's healthcare!

This Biocluster aims to establish Marseille as a world-class center for immunotherapy. Involving public and private players, MIB brings together experts in immunology (research, industry, healthcare, training, start-ups), with strong support from local authorities such as the Aix-Marseille-Provence Metropolis, the Bouches-du-Rhône Department and the Provence-Alpes-Côte-d’Azur Region.

About

Marseille Immunology Biocluster, a vision for the future

Marseille Immunology Biocluster (MIB) is a winning project in France’s national “Bioclusters” call for projects, with a government investment of €96 million.

€96 million

State investment

It brings together major players in research, healthcare, innovation and local authorities, and aims to accelerate the development of immunotherapy antibodies against serious diseases such as inflammatory and autoimmune diseases, cancers and infections.

Marseille Immunology Biocluster (MIB) is a winning project in France’s national “Bioclusters” call for projects, with a government investment of €96 million.

News

Latest news

12.11.2024

MIB: Press kit November 8, 2024

press room

13.11.2024

press release : MIB launched

press room

Denis Bertin

Testimonials

“Bringing together clinicians, researchers and entrepreneurs to develop new drug candidates, MIB is set to transform the management of inflammatory, autoimmune and infectious diseases.”

Denis Bertin,
Vice-Chairman of the Amidex Foundation
France 2030 Coordinator

Marie Roumieux

Testimonials

“To build this world-class immunology innovation cluster, we are providing state-of-the-art technology platforms, including a clinical trials unit in immunotherapy that is unique in terms of the indications treated, to accelerate current R&D projects and develop new French drugs.”

Marie Roumieux,
Scientific Operations Manager

Norbert Vey

Testimonials

“MIB will accelerate the development of drug candidates thanks to a common strategy, with the aim of creating a more fluid link between academic research and industrial development.”

Norbert Vey,
Managing Director, Institut Paoli-Calmettes

Daniel Olive

Testimonials

“MIB is not only interested in oncology, but also in infectious, inflammatory and autoimmune diseases. There is therefore a broad spectrum of pathologies on which we can imagine using innovative therapeutic agents in a variety of ways.”

Daniel Olive,
MIB Project Scientific and Technical Manager